Patanjali Ayurved

Corporate brand

Indian Ayurvedic consumer-goods and conglomerate business spanning food, personal care, cosmetics, traditional medicines and wellness products.

Last updated October 21, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Patanjali Ayurved is an Indian consumer-goods company and holding business established in 2006 by yoga teacher and public figure Ramdev and entrepreneur Acharya Balkrishna. Based in Haridwar, Uttarakhand, the business operates within the wider Patanjali Group and markets products using Ayurvedic, herbal, traditional and “swadeshi” positioning. Its portfolio covers packaged foods, edible oils, beverages, personal care, oral care, cosmetics, health supplements and Ayurvedic medicines. The company has also extended the Patanjali name into retail, apparel, telecommunications-related services and large-scale manufacturing and agricultural projects. Patanjali’s commercial proposition combines low or accessible pricing, Indian sourcing, traditional formulations and a strong association with yoga and Ayurveda. Ramdev has served as the public representative and principal promoter of the business, while Balkrishna has held the chief executive role and the dominant ownership stake. The company’s visibility has been amplified through Ramdev’s television appearances, yoga networks, retail outlets, distributors and direct promotional activity. This model helped Patanjali move rapidly from a specialist Ayurvedic operation into a broad fast-moving consumer-goods competitor to established Indian and multinational companies. Its principal manufacturing base is the Patanjali Food and Herbal Park near Haridwar. Products are distributed through company-linked outlets, general retail, modern trade, online channels and partnerships with major retail groups. The business has also pursued additional production capacity and food-processing investments in other parts of India. Patanjali entered apparel through Patanjali Paridhan and partnered with BSNL in 2018 on the Swadeshi Samriddhi SIM-card initiative, illustrating the group’s willingness to use the brand beyond conventional consumer products. The company has attracted significant public and regulatory scrutiny. Authorities and courts have challenged a number of advertising and product claims, including claims concerning disease treatment, infertility, traditional medicines and COVID-19. The Coronil episode in 2020 and 2021 became the most internationally visible controversy after Patanjali promoted the product in terms that suggested it could cure COVID-19, despite the absence of accepted evidence supporting that claim. Later proceedings concerning alleged misleading advertisements led to restrictions on advertising, public apologies and action affecting several product licences. Patanjali has also faced disputes involving product quality, environmental allegations, labour conditions, advertising directed at competitors and statements critical of allopathic medicine. Despite these controversies, Patanjali remains an important Indian brand in Ayurvedic consumer goods. Its influence comes from the combination of a large domestic distribution system, strong founder-led publicity, broad product coverage and an identity built around Indian tradition and wellness. The brand’s corporate scope, however, is wider than its consumer-products image: the wider group has pursued food parks, hospitals, insurance and other ventures. Financial data should be interpreted carefully because Patanjali Ayurved itself is unlisted and reported figures may relate to different entities within the group.

History

Ramdev and Balkrishna founded Patanjali Ayurved in 2006. The company emerged from the commercial ecosystem surrounding yoga, Ayurveda and herbal remedies, but its ambitions soon extended into mass-market consumer goods. Balkrishna became the principal shareholder and chief executive, while Ramdev became the organization’s most visible public advocate and participated in strategic decisions. The business’s identity emphasized Indian production, traditional knowledge and an alternative to multinational consumer brands. During the 2010s, Patanjali broadened its assortment from Ayurvedic medicines and herbal products into flour, edible oils, ghee, honey, beverages, packaged foods, toothpaste, cosmetics and household-oriented personal care. Its growth was supported by a combination of company-linked stores, distributors, online sales and access to modern retail. Partnerships with Future Group and availability through other large retailers helped the products reach consumers outside specialist Ayurvedic channels. By the middle of the decade, the company was widely described by financial and business analysts as one of India’s fastest-growing FMCG competitors. The Patanjali Food and Herbal Park in Haridwar became the central manufacturing site. The group also planned additional facilities and food-processing investments in locations including Noida, Nagpur and Indore. The scale of the operation led to enhanced industrial security at the Haridwar park. Alongside its core product business, Patanjali experimented with adjacent categories: it launched Patanjali Paridhan in apparel and partnered with BSNL on the Swadeshi Samriddhi SIM-card initiative. These moves reflected a broader group strategy rather than a narrowly defined medicine brand. Patanjali’s expansion was accompanied by repeated criticism of product claims, quality controls and promotional methods. Regulators questioned the authorization of the company’s instant noodles and reported quality concerns involving mustard oil and amla juice. The company also faced objections to claims made for products promoted for diabetes, liver and heart conditions. A dispute over Divya Putrajeevak Seed focused on the product’s name and allegations that it was presented as promising the birth of a male child. Environmental allegations were raised in 2018 concerning runoff and untreated industrial effluent near a Patanjali facility in Haridwar, although company representatives denied violating applicable protocols. Reports about factory conditions also generated criticism regarding long shifts, low pay and the treatment of work as service to the organization. The most consequential controversy began with Coronil. In 2020, Patanjali introduced the product in the context of the COVID-19 pandemic and initially used language that suggested a cure. The Ministry of AYUSH required clarification and the product was subsequently marketed as an immunity booster rather than a proven cure. Courts restricted the use of the Coronil name and imposed a penalty in proceedings concerning the company’s promotional claims. In 2021, Patanjali-associated statements that the product had WHO certification were contradicted by the WHO. Balkrishna later acknowledged that the relevant authorization was for export and did not certify effectiveness against COVID-19. The company’s conflict with the Indian Medical Association intensified after Ramdev made statements attacking allopathic medicine. The IMA pursued legal action and defamation-related claims, while the Supreme Court later scrutinized Patanjali’s advertising practices more broadly. In 2023 and 2024, the court restricted advertisements, demanded apologies and criticized the promotion of unsupported medical claims. The Uttarakhand licensing authority revoked 14 licences during the regulatory response. In August 2024, contempt proceedings against Patanjali, Ramdev and Balkrishna were closed after apologies and corrective measures were accepted, subject to a warning that similar conduct must not recur. Patanjali remains active and continues to operate as a large Indian Ayurvedic and FMCG business. Its present identity is shaped by both its commercial reach and its founder-led, tradition-centered positioning. The company’s activities should be distinguished from those of other Patanjali Group entities, particularly when evaluating financial results, acquisitions or projects reported under the wider group name.

2024
Court proceedings lead to advertising corrections
[1]Patanjali Ayurveden.wikipedia.org
The Supreme Court restricts commercials, requires apologies and precedes licensing action affecting 14 products.
2021
WHO certification claim is disputed
[1]Patanjali Ayurveden.wikipedia.org
The WHO denies certifying Coronil’s effectiveness, and Patanjali clarifies the nature of its authorization.
2020
Coronil controversy begins
[1]Patanjali Ayurveden.wikipedia.org
Patanjali launches Coronil amid claims relating to COVID-19 treatment, triggering regulatory and legal challenges.
2018
Patanjali enters apparel and telecom-related services
[1]Patanjali Ayurveden.wikipedia.org
The company opens Patanjali Paridhan and partners with BSNL on Swadeshi Samriddhi SIM cards.
2016
Major FMCG growth becomes widely recognized
[1]Patanjali Ayurveden.wikipedia.org
Business analysts identify Patanjali as one of India’s fastest-growing FMCG companies, while its retail and manufacturing footprint expands.
2015
Expansion into instant noodles
[1]Patanjali Ayurveden.wikipedia.org
Patanjali introduces instant noodles, prompting questions from food-safety authorities about licensing.
2006
Patanjali Ayurved is founded
[1]Patanjali Ayurveden.wikipedia.org
Ramdev and Balkrishna establish Patanjali Ayurved in India.

Products and positioning

Affordable, Indian-made and tradition-based alternatives to mainstream food, personal-care, wellness and Ayurvedic brands.

Packaged food and staples
Patanjali Food Products
This broad portfolio includes flour, grains, edible oils, ghee, honey, beverages, noodles and other packaged foods. The range uses the Patanjali identity to present everyday staples as Indian, affordable and compatible with traditional or wellness-oriented consumption.
Oral care
Dant Kanti
Dant Kanti is Patanjali’s best-known oral-care line, centered on toothpaste and related dental products. Its marketing emphasizes herbal and Ayurvedic ingredients and positions the range against conventional mass-market toothpaste brands.
Personal care and cosmetics
Patanjali Personal Care and Cosmetics
The personal-care portfolio includes soaps, shampoos, skin-care products, hair-care products and cosmetics. The line extends Patanjali’s natural and herbal positioning into routine household and beauty purchases.
Ayurvedic medicine and supplements · 2006
Divya and Patanjali Ayurvedic Medicines
These products include traditional Ayurvedic preparations, herbal supplements and medicines sold through Patanjali and Divya channels. They have been central to the brand’s identity, while also attracting regulatory attention over disease-treatment claims and product authorization.
Ayurvedic and wellness product · 2020
Coronil
Coronil was introduced during the COVID-19 pandemic and initially promoted in terms suggesting that it could cure the disease. Following regulatory and court challenges, Patanjali’s permitted positioning was narrowed to an immunity-related product rather than a proven COVID-19 cure.
Apparel retail · 2018
Patanjali Paridhan
Patanjali Paridhan is the group’s clothing and apparel initiative. Its Delhi launch in 2018 represented an extension of the brand into a category outside food, personal care and Ayurvedic wellness.

Controversies

2024
Supreme Court misleading-advertising proceedings
The Supreme Court restricted Patanjali advertisements and required apologies in proceedings concerning unsupported health claims. The Uttarakhand licensing authority revoked 14 product licences during the regulatory response.
Source
2023
Allegation concerning animal-derived material in a vegetarian product
A Delhi law firm issued a notice alleging that a dental-care product contained cuttlefish bone despite being presented as vegetarian. The allegation was reported as a legal dispute rather than an established finding.
Source
2022
Dispute over statements attacking allopathic medicine
The Indian Medical Association pursued legal action after Ramdev made statements criticizing evidence-based and allopathic medicine while promoting Patanjali products.
Source
2021
Disputed WHO and government approval claims
Patanjali-associated statements implied WHO certification and government approval of Coronil’s efficacy. The WHO rejected the certification implication, and the company clarified that its authorization did not constitute proof of treatment effectiveness.
Source
2020
Coronil COVID-19 treatment claims
Patanjali’s launch claims were challenged because available evidence did not establish Coronil as a safe or effective cure for COVID-19. Authorities, courts and multiple jurisdictions took steps to limit or clarify the product’s promotion.
Source
2020
Patanjali ordered to pay ₹75.08 crore over GST benefits
India's National Anti-Profiteering Authority ordered Patanjali Ayurveda Ltd to pay ₹75.08 crore, plus 18% GST, for not passing GST rate-reduction benefits on to consumers. The authority said the company increased washing-powder prices and directed it to deposit the amount in consumer welfare funds within three months.
Source
2018
Environmental allegations near Haridwar facility
Residents alleged that runoff from a Patanjali-linked facility polluted local water channels and harmed animals. The environmental authority ordered clean-up measures; the company denied breaching established protocols.
Source
2017
Chyawanprash advertising dispute
The Delhi High Court ordered Patanjali to stop airing an advertisement for chyawanprash that was found to disparage a competitor.
Source
2015
Product licensing and quality disputes
Food-safety authorities questioned approvals for Patanjali instant noodles, while reported testing also raised concerns about the quality of some products including mustard oil and amla juice.
Source
2015
Divya Putrajeevak Seed controversy
Critics objected to the product’s name and alleged that some sellers presented it as promising the birth of a boy. Government bodies examined whether the product conflicted with Indian laws concerning sex selection and reproductive claims.
Source

Swadeshi and Ayurvedic brand platform
India
Patanjali’s long-running marketing platform combines Indian manufacturing, Ayurveda, herbal ingredients, yoga-associated wellness and criticism of multinational consumer brands. Ramdev’s public profile is a central distribution and awareness mechanism for the campaign.
Outcome. Helped establish Patanjali as a mass-market alternative to established Indian and multinational FMCG brands.
Source

Brand decisions

2024
Correct advertising practices after Supreme Court actionStrategy
Background
Court proceedings focused on alleged misleading medical and wellness claims in Patanjali advertising.
Action taken
The company issued newspaper apologies and took corrective steps after advertising restrictions and licensing action.
Aftermath
Contempt proceedings were closed after the apologies were accepted, with a warning that future violations would not be tolerated.
Source
2020
Launch Coronil during the COVID-19 pandemicProduct launch
Background
Demand for products presented as protective or therapeutic increased sharply during the pandemic.
Action taken
Patanjali launched Coronil and initially promoted it with claims suggesting that it could cure COVID-19.
Aftermath
Authorities and courts challenged the claims, the permitted positioning was narrowed, and the company faced fines, restrictions and litigation.
Source
2018
Extend the brand beyond core consumer goodsStrategy
Background
Patanjali’s growth strategy increasingly treated the brand as a wider Indian lifestyle and services platform.
Action taken
The group opened Patanjali Paridhan and partnered with BSNL on Swadeshi Samriddhi SIM cards.
Aftermath
The initiatives increased the brand’s category breadth, although its strongest identity remained in food, personal care and Ayurveda.
Source
2015
Enter the instant-noodles categoryProduct launch
Background
Patanjali was broadening from Ayurvedic and personal-care products into everyday packaged foods.
Action taken
The company introduced instant noodles under the Patanjali and Aayush names.
Aftermath
Food-safety authorities questioned whether the relevant brand licences covered the product.
Source

Recent events

2022-01-31
PNB and Patanjali launch co-branded contactless credit cards[3]旁遮普国家银行与Patanjali推出联名非接触式信用卡freepressjournal.in
Reported: 2022-01-31
Punjab National Bank and Patanjali Ayurved Limited launched co-branded contactless credit cards on NPCI’s RuPay platform, in Platinum and Select variants.
2022-01-10
Patanjali announces discounts on Coronil kits[4]Patanjali 宣布 Coronil 套装折扣businesstoday.in
Reported: 2022-01-10
Patanjali Ayurved announced discounts of 25% on Coronil kits at its centres and 40% for qualifying bulk or institutional purchases.
2021-06-02
Ruchi Soya acquires Patanjali noodles and breakfast cereal business[5]Ruchi Soya收购Patanjali方便面及早餐谷物业务economictimes.indiatimes.com
Reported: 2021-06-15
Ruchi Soya said it acquired the noodles and breakfast cereal business from Patanjali Ayurved Limited under an assignment agreement dated June 2, 2021.
2020-06-23
Patanjali launches Coronil and Coronakit[6]Patanjali推出Coronil及Coronakitindiatvnews.com
Reported: 2020-06-23
Patanjali Ayurved launched Coronil with Coronakit and claimed that the medicine could treat COVID-19. The reported treatment claims were attributed to the company and its co-founder; the article also reports that the government subsequently restricted promotion of the medicine.
2020-06-23
Patanjali announces Coronil[7]Patanjali 宣布推出 Coronilhindustantimes.com
Reported: 2020-06-23
Patanjali announced the launch of Coronil, an Ayurvedic medicine that the company claimed would treat COVID-19. The article reports the claim but does not establish that the medicine cures or treats the disease.
2020-03-12
Patanjali ordered to pay ₹75.08 crore over GST benefits[2]Patanjali ordered to pay ₹75.08 crore over GST benefitseconomictimes.indiatimes.com
Reported: 2020-03-16
India’s National Anti-Profiteering Authority ordered Patanjali Ayurveda Ltd to pay ₹75.08 crore, plus 18% GST, for not passing GST rate-reduction benefits on to consumers. The authority said the company increased washing-powder prices and directed it to deposit the amount in consumer welfare funds within three months.
2019-12-18
Patanjali completes acquisition of Ruchi Soya[8]Patanjali 完成对 Ruchi Soya 的收购financialexpress.com
Reported: 2019-12-18
Patanjali Ayurved completed its acquisition of Ruchi Soya for Rs 4,350 crore through an insolvency process. A Patanjali spokesperson said the debt and equity had been deposited and Ruchi Soya had officially become a Patanjali group firm.
2019-11-29
Patanjali secures financing for planned Ruchi Soya acquisition[9]Patanjali为计划收购Ruchi Soya落实融资thehindubusinessline.com
Reported: 2019-11-29
Patanjali Ayurved said it had tied up loans worth Rs 3,200 crore from a consortium of lenders to fund its planned acquisition of Ruchi Soya through the insolvency process.
2019-11-29
Banks agree to fund Patanjali’s acquisition of Ruchi Soya[10]银行同意为Patanjali收购Ruchi Soya提供融资newindianexpress.com
Reported: 2019-11-29
A consortium of lenders led by State Bank of India decided to fund Patanjali’s acquisition of Ruchi Soya. Patanjali’s managing director said ₹3,200 crore of the approved resolution plan would be funded through debt from a consortium of banks.

Sources22 sources

Cite this profile: Cite the canonical profile. /brand-wiki/patanjali-ayurved · Editorial policy · How profiles are compiled